Immune-Onc Therapeutics Selected for Oral Presentation at American Society of Hematology (ASH) Annual Meeting to Showcase New Data from Phase 1b Study of IO-202 in Chronic Myelomonocytic Leukemia
PALO ALTO, CA, November 5, 2024 - Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private clinical-stage biopharmaceutical company advancing novel therapies in immunology and oncology by targeting myeloid cell inhibitory receptors, today announced that the latest data from the Phase 1b expansion cohort of its first-in-class anti-LILRB4 antibody, IO-202, in combination with azacitidine (AZA) for the treatment of chronic myelomonocytic leukemia (CMML), has been selected for an oral presentation at the 2024 American Society of Hematology (ASH) Annual Meeting, to be held December 7-10 in San Diego, California.
New data beyond what was published in the ASH abstract #1008 will be included in the oral presentation on December 9, 2024.
Oral presentation details:
Publication Number: 1008
Title: IO-202, a Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results
Presenter: Gabriel N. Mannis, M.D., associate professor of medicine, division of hematology, Stanford Cancer Institute, Stanford University
Session Date and Time: Monday, December 9, 2024: 4:30 PM - 6:00 PM PT
Presentation Time: 5:45 PM PT
Room: Manchester Grand Hyatt San Diego, Grand Hall D